News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

A5 Labs Completes Validation of CRO Equipment


8/31/2010 11:48:08 AM

MONTREAL, QUEBEC--(Marketwire - August 31, 2010) - A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) today announced the CRO team headed by Dr. Matni has completed the validation of the first set of equipment that will be used for the testing of pharmaceutical raw materials and finished products. The company expects to complete the validation of the all remaining CRO equipment by the end of September 2010. Consequently the company plans to finalize its CRO testing and analytical standard operating procedures (SOPs) in October 2010.

"I am very pleased to report to our customers and shareholders the completion of the validation of our equipment. We are rapidly approaching the completion of our entire laboratory infrastructure; which we believe will create a world class CRO company," said Dr. Richard Azani, President and CEO.

About A5 Labs:

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.


Contacts:
A5 Laboratories Inc.
Investor Relations
1-877-331-8777
ir@a5labs.com


Read at BioSpace.com

comments powered by Disqus
A5 Labs
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES